TARGETED THERAPY, KINASE INHIBITOR
Kisqali is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an initial endocrine-based treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women. Kisqali is also referred to by its drug name, ribociclib.
Kisqali is a targeted therapy in a class of drugs called cyclin-dependent kinase (CDK) inhibitors. In tandem with an aromatase inhibitor, Kisqali is believed to work by slowing the growth and preventing the spread of tumors.
How do I take it?
Prescribing information states that Kisqali is taken once daily.
Kisqali comes in tablet form.
The FDA-approved label for Kisqali lists common side effects including low blood cell count, nausea, infections, fatigue, diarrhea, vomiting, hair loss, headache, constipation, rash, and cough.
Rare but serious side effects listed for Kisqali include lung disease, skin reactions, liver damage, severe birth defects, changes in heart rhythm, and severe blood cell disorders.
For more details about this treatment, visit:
Kisqali — Novartis